Saturday, November 14, 2026

Federal Reserve Cuts Rates to 3.5-3.75% After 16-Month Hiking Campaign That Reshaped Global Borrowing Costs

The Federal Reserve's benchmark rate fell to 3.5-3.75% by January 2026 after the sharpest tightening cycle in four decades pushed rates from near-zero in early 2022. The aggressive hiking campaign drove mortgage rates above 8%, froze housing markets, and inflicted $500 billion in unrealized losses on U.S. financial institutions holding long-duration securities. The Fed began cutting in September 2024, but maintains a cautious pace as global central banks navigate the inflation-growth trade-off.

ViaNews Editorial Team

February 26, 2026

From our archive, published before source-traceability. How we work

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Federal Reserve Cuts Rates to 3.5-3.75% After 16-Month Hiking Campaign That Reshaped Global Borrowing Costs
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Federal Reserve's benchmark rate stood at 3.5-3.75% in January 2026, down from peaks reached in mid-2023 after a 16-month hiking campaign that began March 2022. The central bank initiated rate cuts in September 2024, its first easing in over four years, following a tightening cycle that produced the sharpest borrowing cost increases in four decades.

The policy shift echoed across global financial markets as central banks worldwide navigated similar inflation pressures. The European Central Bank and Bank of England implemented parallel tightening cycles, though the Fed's aggressive pace set the baseline for international borrowing costs. Mortgage rates in the U.S. exceeded 8% at peak, pricing millions out of homeownership—a dynamic mirrored in Canada, Australia, and the UK where property markets froze under similar rate pressure.

U.S. financial institutions absorbed severe balance sheet stress. Banks holding long-duration securities faced unrealized losses exceeding $500 billion at the cycle's peak, with Treasury yield curve inversions persisting for extended periods. Regional banks particularly struggled with funding cost stickiness as depositors demanded competitive rates even during the easing phase, compressing net interest margins.

Manufacturing activity contracted for 26 consecutive months through the cycle's later stages. Rate-sensitive sectors including trucking, construction equipment, and commercial real estate faced acute pressure. Corporate borrowers rushed to refinance floating-rate debt during the easing phase, while high-yield bond issuance surged in late 2024 and early 2025 as companies locked in lower rates.

The Fed's measured easing pace—slower than previous cutting cycles—reflects persistent inflation concerns shared by central banks globally. The policy achieved its primary inflation-fighting objective but left financial institutions navigating compressed margins and stressed commercial real estate portfolios. Market participants expect rates to hold near current levels through mid-2026, with further cuts contingent on inflation data and labor market stability—a cautious stance that contrasts with more aggressive easing cycles in previous decades.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· February 2, 2026
    Kevin Warsh’s Fed Will End the War on Main Street and Trucking

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com